Показано 0 из 0
Дата |
---|
11:00 |
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
4.51
|
4.92
|
4.50
|
4.50
|
4.50
|
4.50
|
|
|
|
|
4.60
|
4.98
|
4.51
|
4.51
|
4.51
|
4.51
|
|
|
|
|
4.60
|
5.08
|
5.62
|
5.62
|
5.62
|
5.62
|
|
|
|
|
5.86
|
6.10
|
6.16
|
6.16
|
6.16
|
6.16
|
|
|
|
|
6.16
|
6.66
|
6.16
|
6.16
|
6.16
|
6.16
|
|
|
|
|
6.40
|
6.68
|
6.26
|
6.26
|
6.26
|
6.26
|
|
|
|
|
6.34
|
6.42
|
6.20
|
6.20
|
6.20
|
6.20
|
|
|
|
|
6.20
|
6.60
|
6.60
|
6.40
|
6.60
|
6.40
|
|
|
640.00
|
2.00
|
6.66
|
6.96
|
6.76
|
6.76
|
6.90
|
6.90
|
|
|
345.00
|
2.00
|
6.78
|
7.02
|
6.90
|
6.90
|
6.90
|
6.90
|
|
|
|
|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development.